Isolated post-challenge hyperglycaemia predicts increased cardiovascular mortality

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 194-199

  Silbernagel, Guenther ^a,b   Sourij, Harald ^c   Grammer, Tanja B ^d   Kleber, Marcus E ^a,d   Hartaigh, Bríain O ^e   Winkelmann, Bernhard R ^f   Boehm, Bernhard O ^g   März, Winfried ^c,d,h  

^a LURIC Study Nonprofit LLC   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f Cardiology Group Frankfurt Sachsenhausen   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h SYNLAB ACADEMY   (Germany)

Author keywords

All cause mortality; Cardiovascular mortality; Diabetes classification; Glycated haemoglobin; Oral glucose tolerance test; Post challenge hyperglycaemia; Type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART DEATH; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED;

EID: 84867864239     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.008     Document Type: Article

References (30)

1. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
2. Schramm T.K., Gislason G.H., Køber L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117:1945-1954.
3. Silbernagel G., Rosinger S., Grammer T.B., et al. Duration of type 2 diabetes strongly predicts all-cause and cardiovascular mortality in people referred for coronary angiography. Atherosclerosis 2012, 221:551-557.
4. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32(Suppl. 1):S62-S67.
5. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(Suppl. 1):S62-S69.
6. Selvin E., Crainiceanu C.M., Brancati F.L., Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007, 167:1545-1551.
7. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J. A1c-derived average glucose study group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008, 3:1473-1478.
8. Colagiuri S., Lee C.M., Wong T.Y., Balkau B., Shaw J.E., Borch-Johnsen K., DETECT-2 Collaboration Writing Group Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011, 34:145-150.
9. de Vegt F., Dekker J.M., Ruhé H.G., et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42:926-931.
10. Pfister R., Sharp S.J., Luben R., Khaw K.T., Wareham N.J. No evidence of an increased mortality risk associated with low levels of glycated haemoglobin in a non-diabetic UK population. Diabetologia 2011, 54:2025-2032.
11. Gerstein H.C., Swedberg K., Carlsson J., CHARM Program Investigators, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008, 168:1699-1704.
12. Selvin E., Steffes M.W., Zhu H., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
13. Silbernagel G., Grammer T.B., Winkelmann B.R., Boehm B.O., März W. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care 2011, 34:1355-1361.
14. Silbernagel G., Kleber M.E., Grammer T.B., Winkelmann B.R., Boehm B.O., März W. Additional use of glycated hemoglobin for diagnosis of type 2 diabetes in people undergoing coronary angiography reveals a subgroup at increased cardiovascular risk. Diabetes Care 2011, 34:2471-2473.
15. Selvin E., Steffes M.W., Gregg E., Brancati F.L., Coresh J. Performance of glycated hemoglobin for the classification and prediction of diabetes. Diabetes Care 2011, 34:84-89.
16. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999, 354:617-621.
17. Shaw J.E., Hodge A.M., de Courten M., Chitson P., Zimmet P.Z. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999, 42:1050-1054.
18. Bartnik M., Malmberg K., Norhammar A., Tenerz A., Ohrvik J., Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25:1990-1997.
19. Lenzen M., Ryden L., Ohrvik J., et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006, 27:2969-2974.
20. Barr E.L., Zimmet P.Z., Welborn T.A., et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157.
21. Webb D.R., Gray L.J., Khunti K., et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 2011, 54:2237-2246.
22. Sourij H., Saely C.H., Schmid F., et al. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J 2010, 31:1583-1590.
23. Kramer C.K., Araneta M.R., Barrett-Connor E. A1C and diabetes diagnosis: the Rancho Bernardo study. Diabetes Care 2010, 33:101-103.
24. Boronat M., Saavedra P., López-Ríos L., Riaño M., Wägner A.M., Nóvoa F.J. Differences in cardiovascular risk profile of diabetic subjects discordantly classified by diagnostic criteria based on glycated hemoglobin and oral glucose tolerance test. Diabetes Care 2010, 33:2671-2673.
25. Winkelmann B.R., Marz W., Boehm B.O., LURIC Study Group (Ludwigshafen Risk and Cardiovascular Health), et al. Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2000, 2(1 Suppl. 1):S1-S73.
26. Friesinger G.C., Page E.E., Ross R.S. Prognostic significance of coronary arteriography. Trans Assoc Am Physicians 1970, 83:78-92.
27. de Groot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
28. Rizza S., Cardellini M., Martelli E., et al. Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation. Atherosclerosis 2010, 212:316-320.
29. Standl E., Schnell O., Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care?. Diabetes Care 2011, 34(Suppl. 2):S120-S127.
30. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.